Video

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

Marc Bjurlin, DO, clinical assistant professor, department of urology, New York University (NYU) Langone Medical Center, discusses predictive models for prostate cancer risk.

One of the controversies in prostate cancer is which men require a prostate biopsy and of those men, which have a risk of having clinically significant cancer that warrants treatment, explained Bjurlin.

Bjurlin’s team built predictive models that can determine the likelihood of having cancer and of having high-risk disease. They did this using several different clinical parameters, including a multiparametric MRI of the prostate. This is used in conjunction with PSA and family history to determine if patients should get a biopsy and their likelihood of having clinically significant prostate cancer.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine